CEO SUMMARY: With the advent of 2013, almost every lab was responding to some type of price cut. Clinical labs are dealing with the sequential, multi-year cuts to the Medicare Part B Lab Test Price Schedule. Anatomic pathology labs are still adjusting to the expiration of the TC Grandfather clause last summer, as well as […]
Anticipating Washington’s Next Blows to Lab Testing
Even as laboratories react to reduced revenue from multiple cuts in lab prices, more is to come
- By Robert Michel
- > From the Volume XX No. 4 - March 25, 2013 Issue
- Tags: accountable care, Accountable care organizations, acla, aco, american clinical lab, american clinical laboratory, Anatomic pathology, anatomic pathology lab, anatomic pathology labs, cap, clinical lab, clinical lab test, clinical lab testing, clinical laboratories, Clinical Laboratory, clinical labs, clinical testing, cpt, cpt code, dark report, ehr, executive war college, Fee-for-service, gene sequencing, lab administrator, lab industry, lab leader, lab manager, lab managers, lab test, lab testing, lab testing services, lab tests, laboratories, laboratory association, laboratory medicine, laboratory organization, laboratory organizations, laboratory test, laboratory testing, laboratory testing services, m-lab, mass spec, mass spectrometry, Meaningful Use, meaningful use criteria, medical home, medical homes, Medicare, Medicare Part B, new diagnostic technologies, next-generation gene sequencing, pathologists, Pathology group, pathology groups, pathology lab, pathology labs, pathology management, private payer, ran whitehead, the dark report, Value-based reimbursement
